Welcome to our dedicated page for PEAR news (Ticker: PEAR), a resource for investors and traders seeking the latest updates and insights on PEAR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PEAR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PEAR's position in the market.
Pear Therapeutics, Inc. (NASDAQ: PEAR) collaborates with the S.C. Department of Corrections to implement FDA-authorized prescription digital therapeutics (PDTs) at the Camille Griffin Graham Correctional Institution in Columbia, S.C. This initiative aims to aid women inmates with substance use disorders, offering treatments like reSET® and reSET-O®. Funded by the S.C. Department of Alcohol and Other Drug Abuse Services, this unique program addresses the high incidence of addiction among incarcerated individuals. Such innovative treatments are designed to enhance recovery and provide clinicians with tools to monitor patient progress.
Pear Therapeutics, Inc. (NASDAQ: PEAR) will participate in Citi's 17th Annual BioPharma Conference on September 7-8, 2022, in Boston. Dr. Yuri Maricich, the Chief Medical Officer, will join a panel discussion on Mental Health at 10:30 a.m. ET on September 7. The company will also hold one-on-one meetings for investors during the conference. A live audio webcast of the presentation will be accessible here and available on Pear's website for 30 days afterwards.
Pear Therapeutics reported a strong second quarter for 2022, achieving a 20% revenue growth quarter-over-quarter, reaching $3.3 million from $2.7 million in Q1 2022. The company's total prescriptions exceeded 11,000, although the fulfillment and payment rates were 56% and 45%, respectively. Pear announced new telehealth partnerships and expanded patient access in eight states for its FDA-authorized prescription digital therapeutics. Recent studies showed significant cost savings and improved health outcomes for patients, reinforcing the value of Pear's offerings.
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced a new health economic analysis highlighting the benefits of Somryst®, the only FDA-authorized prescription digital therapeutic for chronic insomnia. The analysis showed a $2,059 reduction in per-patient costs over 24 months and significant decreases in health-related services such as a 53% reduction in emergency department visits. Additionally, patients experienced a 37.2% reduction in insomnia severity index scores at nine weeks, indicating substantial clinical efficacy.
Pear Therapeutics, Inc. (NASDAQ: PEAR) has partnered with SelectHealth to provide its members covered access to reSET-O, the FDA-authorized prescription digital therapeutic for treating opioid use disorder (OUD). This benefit will support outpatient treatment involving transmucosal buprenorphine.
SelectHealth serves over 1 million members across Utah, Idaho, and Nevada, and aims to enhance care accessibility and outcomes for individuals facing addiction, aligning with the nation’s strategy to combat the opioid crisis.
Pear Therapeutics has partnered with Cove Behavioral Health to provide access to its FDA-authorized digital therapeutic reSET-O® for opioid use disorder (OUD) through a State Opioid Response (SOR) grant. This program, based in Tampa Bay, Florida, aims to help OUD patients by increasing treatment retention.
Cove serves over 30,000 individuals annually and will offer reSET-O in both English and Spanish. The initiative underscores efforts to combat the opioid crisis, particularly in areas experiencing high overdose rates.
Pear Therapeutics (NASDAQ: PEAR) has been added to the Russell US Index Series as of September 19, 2022. This inclusion is significant as Russell indexes are benchmarks for $12 trillion in assets managed by investment firms. Pear Therapeutics specializes in prescription digital therapeutics (PDTs) and aims to enhance patient outcomes through innovative software-based medicines. Their product lineup includes the first FDA-authorized PDTs for substance use disorder and chronic insomnia.
Pear Therapeutics, Inc. (NASDAQ: PEAR) will announce its second quarter 2022 financial results after market close on August 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss financial and business highlights. Participants can register online to access the call and a replay will be available on the company's website two hours post-call. Pear Therapeutics is known for its software-based medicines called prescription digital therapeutics (PDTs), including FDA-approved products for substance use disorder and chronic insomnia.
Pear Therapeutics, Inc. (Nasdaq: PEAR) will participate in Cowen’s 7th Annual FutureHealth Conference on June 22-23, 2022. CEO Corey McCann will engage in a panel discussion titled, “Commercializing Prescription Digital Therapeutics,” on June 23 at 12:40 p.m. ET. Pear Therapeutics specializes in developing prescription digital therapeutics (PDTs) to enhance patient care, clinician engagement, and cost-effectiveness for payers. Their notable products include reSET®, reSET-O®, and Somryst®, addressing substance use disorder, opioid use disorder, and chronic insomnia, respectively.
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced the election of Paul Mango, Shiva Rajaraman, and Tim Wicks to its Board of Directors during the Annual Meeting held on June 14, 2022. The company aims to enhance the healthcare landscape through its software-based medicines known as prescription digital therapeutics (PDTs). The newly appointed members bring extensive experience in healthcare and technology, contributing to Pear's strategic direction. The board now consists of seven directors, with six being independent, reflecting diverse expertise in critical areas.
